



# Pneumococcal Vaccines

**Katherine A. Poehling, MD, MPH**

Pneumococcal Vaccines Work Group Chair  
Advisory Committee on Immunization Practices  
February 22, 2023

# Pneumococcal Vaccines Work Group

## ACIP Members

- Katherine Poehling (Chair)
- Sarah Long

## Ex Officio Members

- Jeffrey Kelman (CMS)
- Lucia Lee (FDA)
- Tina Mongeau (FDA)
- Uzo Chukwuma (IHS)
- Mamodikoe Makhene (NIH)

## CDC Lead

- Miwako Kobayashi (NCIRD)

## Liaison Representatives and Consultants

- Lynn Fisher (AAFP)
- Mark Sawyer (AAP/COID)
- Jason Goldman (ACP)
- David Nace (AGS/AMDA)
- Aleksandra Wierzbowski (NACI)
- James McAuley (IDSA)
- William Schaffner (NFID)
- Virginia Caine (NMA)
- Monica Farley (VAMC/Emory)
- Keith Klugman (BMGF)
- Arthur Reingold (UC Berkley)
- Lorry Rubin (CCMC)
- Richard Zimmerman (U. of Pittsburgh)

# Pneumococcal Vaccines Work Group





## **CDC Contributors**

- Adam Cohen (Respiratory Diseases Branch)
- Ryan Gierke (Respiratory Diseases Branch)
- Jennifer Farrar (Respiratory Diseases Branch)
- Pedro Moro (Immunization Safety Office)
- Liz Velazquez (Immunization Services Division)
- Marc Fischer (Arctic Investigations Program)
- Noele Nelson (Division of Bacterial Diseases)
- Jessica MacNeil (ACIP Secretariat)

## **GRADE/EtR consultants**


- Doug Campos-Outcalt
- Rebecca Morgan

## Pneumococcal vaccines currently recommended for use in the United States

	Recommended for children	Recommended for adults
<b>Pneumococcal conjugate vaccines</b>		
PCV13		
PCV15		
PCV20		
<b>Pneumococcal polysaccharide vaccine</b>		
PPSV23	Risk-based recommendations	If previously received PCV13 or PCV15


## All children under age 2 years have the same pneumococcal vaccine recommendations

- 3 primary series and a booster="3+1" schedule



Either **PCV13** or **PCV15** can be used for U.S. children.

## Children with certain underlying conditions are recommended to **receive PPSV23** in addition to the recommended PCV doses




**Note:** Excludes catch-up vaccination schedules.

CMC=chronic medical conditions, including chronic heart disease, chronic lung disease, diabetes mellitus

CSF=cerebrospinal fluid

[Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR \(cdc.gov\)](#)

# Approval of PCV20 use among Children Anticipated in 2023



[U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children | Pfizer](#)

## Policy questions considered by the Work Group

- Should **PCV20** be recommended as an option for pneumococcal conjugate vaccination **according to currently recommended dosing and schedules, for U.S. children aged <2 years?**
- Should **PCV20 without PPSV23** be recommended as an option for pneumococcal vaccination **for U.S. children aged 2–18 years with underlying medical conditions that increase the risk of pneumococcal disease?**



# Today's Pneumococcal Vaccines session outline

Introduction

Dr. Katherine Poehling  
(ACIP, WG Chair)

Epidemiology of pneumococcal disease among  
U.S. children

Mr. Ryan Gierke  
(CDC/NCIRD)

Pediatric outpatient ARI visits and antibiotic use  
attributable to serotypes in higher valency PCVs

Ms. Laura King  
(U.C. Berkeley)

PCV20 phase 2/3 study results among children

Dr. Wendy Watson  
(Pfizer)

Preliminary EtR for PCV20 use in U.S. children

Dr. Miwako Kobayashi  
(CDC/NCIRD)

Work Group considerations and next steps

Dr. Miwako Kobayashi  
(CDC/NCIRD)